Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124

This document outlines details of PBS-subsidised elotuzumab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma (MM).

MM and listing dates

MM is a type of blood cancer.

Listing dates:

• lenalidomide - 1 November 2009
• pomalidomide - 1 August 2015
• elotuzumab - 1 May 2022
• selinexor - 1 September 2022

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

• application forms
• contact details
• FAQs from Service Officers
• restriction and item codes
• the PBS schedule
• Services Australia website link

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs